Study ID	Intervention(s) and comparator(s)	Participants included in analysis (N)	Deaths (N)	Deaths (% of participants)	Participants with at least one adverse event (N)	Participants with at least one adverse event (%)	Participants with at least one severe/serious adverse event (N)	Participants with at least one severe/serious adverse event (%)
Albino 2010	I1: 0.1 mg rhTSH + radioiodine (1.11 GBq)	8	—	—	4	50	—	—
	I2: 0.01 mg rhTSH + radioiodine (1.11 GBq)	6	0	0	4	66.7	—	—
	C: placebo and radioiodine (1.11 GBq)	8	0	0	3	37.5	—	—
Bonnema 2007	I: 0.3 mg rhTSH + radioiodine (aiming at a thyroid dose of 100 Gy)	14	—	—	12	85.7	—	—
	C: isotonic saline + radioiodine (aiming at a thyroid dose of 100 Gy)	15	—	—	8	53.3	—	—
Cubas 2009	I1: 0.005 mg rhTSH + radioiodine (1.11 GBq)	9	0	0	6	66.6	—	—
	I2: 0.1 mg rhTSH + radioiodine (1.11 GBq)	9	0	0	2	22.2	—	—
	C: placebo and radioiodine (1.11 GBq)	10	1	10	4	40	—	—
Fast 2010	I: 0.1 mg rhTSH + radioiodine (50 Gy)	60	—	—	17	28.3	—	—
	C: placebo + radioiodine (100 Gy)	30	—	—	10	33.3	—	—
Fast 2014	I1: 0.01 mg rhTSH + radioiodine (100 Gy)	30	—	—	26	86.7	—	—
	I2: 0.03 mg rhTSH + radioiodine (100 Gy)	33	—	—	31	93.9	—	—
	C: placebo and radioiodine (100 Gy)	32	—	—	27	84.4	—	—
Nielsen 2006	I: 0.3 mg rhTSH + radioiodine (calculated based on thyroid size, thyroid 131I uptake, and 131I half‐life)	28	—	—	16	53.6	—	—
	C: placebo + radioiodine (calculated based on thyroid size, thyroid 131I uptake, and 131I half‐life)	29	—	—	10	34.5	—	—
—: denotes not reported 131I: radioactive iodine; C: comparator; GBq: giga Becquerel; Gy: Gray; I: intervention; rhTSH: recombinant human thyrotropin